home.aspx
 
EVENTS

Annual Pharma Pricing, Reimbursement & Market Access Conference
ANNUAL PHARMA PRICING, REIMBURSEMENT & MARKET ACCESS CONFERENCE
December 02-03, 2020
Annual Pharma Pricing, Reimbursement & Market Access will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. It will focus on themes such as Preparing your best market access strategy, EU and US policy ...

Controlled & Modified Drug Release Summit
CONTROLLED & MODIFIED DRUG RELEASE SUMMIT
December 01-03, 2020
By attending the unique Controlled & Modified Drug Release Summit, you will learn directly from 50+ of industry’s leading experts and hear multiple unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies ...

SHARESHARESHARE
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power.
SHARESHARESHARE

RELATED NEWS


Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...
GLOBENEWSWIRE
READ MORE

Last June, 10 major pharmaceutical companies — Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Institut De Recherches Servier, Janssen, Merck, and Novartis — inked an agreement to build a shared platform called MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery). In partnership with Nvidia, Owkin, and other tech partners, the group sought to leverage techniques like federated learning to collectively train AI on datasets without having to share any pro...
VENTUREBEAT
READ MORE

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...
BUSINESS WIRE
READ MORE

Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...

READ MORE

A new collaboration between Bayer and UK-based Exscientia is set to accelerate the discovery of small molecule drugs, focused on cardiovascular disease and oncology. The companies have announced that they will use artificial intelligence (AI) to further the development of drug candidates for three of Bayer’s projects in the areas of cardiovascular disease (CVD) and oncology. Under the terms of the deal, Exscientia will begin by working on three projects with targets agreed between both par...

READ MORE

Bayer, a leading life sciences company, focused on digitally transforming the healthcare sectrtor at the Digital Transformation forum, Digitrans 2019, in Dubai. With a focus on emerging technologies such as AI, 3D technology and IoT, this two-day forum brought together regional leaders from across all industries to discuss best practices and strategies that can fuel the region’s drive to create an innovation-led economy. Providing world-class healthcare is one of the key six pillars of the...

READ MORE

Bayer has continued its policy of setting up R&D hubs to get closer to innovative companies with a UK site that will focus on applying artificial intelligence to drug discovery and disease diagnosis. The cluster – based at Reading’s Green Park – is the seventh in the German company’s LifeHub network, located at R&D hot spots around the globe, and is further evidence of the UK’s leading position in AI technology. According to the Tech Nation 2019 report, the ...

READ MORE

Bayer has announced that the European Medicine Agency (EMA) has licensed its Vitrakvi (larotrectinib) in adults and children with solid tumours displaying Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. The indicated patients must also have either locally advanced or metastatic disease, or be in a situation where there are no adequate treatment options or surgical resection is likely to cause severe morbidity. This makes Vitrakvi the first tumour agnostic drug to be approved in the Eur...

READ MORE

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial in the wet form of AMD will compare brolucizumab against Eylea (aflibercept) on a range of measures, including visual acuity and treatment interval duration, to see if it can outperform Bayer and Regeneron’s drug. An FDA verdict on brolucizumab is due shortly based on two earlier trials &ndas...

READ MORE

What does one of the worst corporate deals in modern history look like? In Bayer’s Monsanto takeover, it means the value of an entire company has gone poof. Bayer acquired Monsanto for $63 billion in 2018 after a tough buyout battle and intense antitrust scrutiny. The German conglomerate’s market cap in Frankfurt today is close to that dollar amount—and that’s after rumors of an $8 billion Roundup settlement drove up its shares by more than 15% in early August. At a 30% l...

READ MORE

EVENTS

Controlled & Modified Drug Release Summit
CONTROLLED & MODIFIED DRUG RELEASE SUMMIT
December 01-03, 2020
By attending the unique Controlled & Modified Drug Release Summit, you will learn directly from 50+ of industry’s leading experts and hear multiple unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies ...

Peptide Drug Design & Delivery Summit
PEPTIDE DRUG DESIGN & DELIVERY SUMMIT
December 01-03, 2020
The Peptide Drug Design & Delivery Summit will bring together key decision makers and innovators within this rapidly growing field. This intensive 3-Day program will examine various peptide discovery and synthesis techniques and synthesized and modified peptides. Hear from over 50 peptide drug c...